Fresenius Medical Care (FMS) PT Lowered to $35 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts FMS Hot Sheet
Price: $21.73 --0%
Rating Summary:
7 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 11
Rating Summary:
7 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 11
Join SI Premium – FREE
RBC Capital analyst Frank Morgan lowered the price target on Fresenius Medical Care (NYSE: FMS) to $35.00 (from $42.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- XPLR Infrastructure (XIFR) PT Lowered to $10 at Scotiabank
- Neutron Holdings (LIME) PT Lowered to $29 at Needham
- Indraprastha Gas Ltd. (IGL:IN) PT Lowered to INR140 at Kotak
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
